Jan 31,2024

Endocrinology company Valendo Health launches with $4M and two provider partners

Valendo Health, a diabetes-focused, value-based endocrinology company, announced its launch with $4 million in seed funding and two providers. The company, built out of Redesign Health, aims to increase revenue for endocrinologists while assisting with the transition to a value-based care model. It offers telehealth and remote patient monitoring services with diabetes care clinicians, an endocrinology-focused EMR, data analytics and assistance with implementing value-based care contracting. The Boston-based company has partnered with two providers: Cecelia Health, a national virtual specialty care provider for chronic care management, and Advanced Metabolic Care + Research, an endocrinology center in Southern California serving patients with diabetes and other metabolic conditions. "At Valendo, we provide endocrinologists the tools to increase clinical capacity and grow practice revenue through virtual care and practice management support, and then we help them transition into value-based contracts." said Dave Terry, CEO and cofounder of Valendo Health.

FUNDING SEED ROUND

#telehealth

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 28,2017

Cognoa Raises $11.6 Million, Reaching More Than $20 Million Invested to Advance Earlier Diagnosis of Developmental Delays in Children

Cognoa, a digital health company revolutionizing how children with developmental delays are diagnosed and supported, today announces $11.6 million in additional funding. Since the company's founding in 2013, Cognoa has raised a total of more than $20 million. The new funding, provided by existing investor Morningside, is being used to advance Cognoa's machine-learning-based technology; support additional clinical validation and the U.S. Food and Drug Administration (FDA) submissions and approvals process; and expand commercialization with employers, payers and clinicians.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jan 26,2024

India-based FlexifyMe Receives Funding to Enhance AI Motion Coach

Chronic pain digital therapeutics platform FlexifyMe has received undisclosed pre-seed funding from angel platform ah! Ventures. In a statement, the startup, which is also backed by Flipkart Ventures, mentioned that they will deploy their latest funds to enhance further their AI motion coach by making it available in more local Indian languages, as well as expanding their reach across North America and the Middle East and North Africa regions.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jan 24,2024

Live tumor imaging company Elephas garners $55M

Elephas, an oncology-focused diagnostics platform, announced it secured $55 million in Series C funding, bringing its total raise to $116.5 million. Venture Investors Health Fund and the State of Wisconsin Investment Board (SWIB) led the round. Existing investors Northpond Ventures, Moore Strategic Ventures, WARF Ventures, Tao Invest, Sands Capital and ARCH Ventures also participated in the raise. Elephas is developing a diagnostics platform to predict a patient's response to immunotherapy using metabolic imaging. The Wisconsin-based company analyzes a tumor's architecture via a patient biopsy and treats it with potential therapies to determine treatment response.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Jan 09,2024

Feel Therapeutics Brings Michel Vounatsos as Chairman Of The Advisory Board, and Secures New Funding

Feel Therapeutics announced today that Michel Vounatsos, former CEO of Biogen, has joined as a Chairman of their Advisory Board. Additionally, Feel has secured new funding from Satori Neuro, Metavallon VC, and existing investors such as SOSV, SeedtoB, and others, to fuel its expansion plans. Along with the new funding, Amy Kruse, Chief Investment Officer of Satori Neuro, has joined the Board of Directors.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Dec 13,2023

Addiction Startup PursueCare Raises $20M

Virtual substance use disorder (SUD) provider PursueCare netted $20 million in a series B fundraising round. T.Rx Capital and Yamaha Motor Ventures led the funding round with participation from Seyen Capital and OCA Ventures. The company has also announced the acquisition of three software products of Pear Therapeutics following its bankruptcy.

FUNDING SERIES B

#cbt

View Analyst & Ambassador Comments
Go to original news
Dec 13,2023 TOP STORY

Twin Health Secures $50M To Expand Its Groundbreaking Whole Body Digital Twin Technology And Service To Reverse Chronic Metabolic Disease

Twin Health, creators of the Whole Body Digital Twin™ service for reversing, improving, and preventing chronic metabolic diseases, announced securing $50 million in funding to continue expanding its groundbreaking technology and clinical service solutions for more members across the United States. The funding is led by Temasek, and the existing investors ICONIQ Growth, Sofina, Peak XV, and Helena also participated in this financing round. Twin Health has expanded its reach with strategic partners in the employer and health plan domains, covering over 4 million lives. Notable achievements include completing the world's first randomized controlled trial (RCT) for reversing chronic metabolic disease using digital twin technology. The one year results, recently published in the American Association of Clinical Endocrinology, showed a significant reduction in HbA1c in the intervention group (2.9% reduction from 9.0 to 6.1) and a significantly higher elimination of diabetes medications (elimination of 94% of type 2 diabetes medications in the intervention group).

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Jun 06,2022

Feel Therapeutics Receives Funding from SeedtoB Capital

Feel Therapeutics, a San Francisco, CA-based developer of digital biomarkers and therapeutics, raised an undisclosed amount in funding from SeedtoB Capital. The company intends to use the funds to accelerate their progress on the path to making data-driven mental health interventions accessible to those who need them.

FUNDING FUNDING ROUND
View Analyst & Ambassador Comments
Go to original news
Nov 21,2023

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth

Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans. Recognizing the challenges associated with equity sales, particularly in the small-cap landscape on the Nasdaq, Nemaura Medical has proactively pursued a funding strategy that minimizes dilution and, the Company believes, aligns with the best interests of its valued shareholders. This $10 million credit facility, structured to be non-dilutive, empowers the Company to draw down a maximum of $1 million per month, providing a steady and controlled infusion of capital to support Nemaura Medical’s commercialization initiatives.

FUNDING NON-DILUTIVE CREDIT FACILITY

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Nov 16,2023 TOP STORY

Lunit receives $150M capital chip-in, doubles down on US market

Shareholders of KOSDAQ-listed Lunit have recently participated in the company's recent capital raise, paying-in $150 million to fund its development of "next-generation" products and further expansion in the West. In a company disclosure, Lunit shared that more than a third or about $52 million of its capital proceeds will go to building new AI cancer diagnostics and therapeutics; $38 million will be invested in its subsidiaries in the United States and Europe; $30 million will be used to invest in external startups; and $15 million each will go to global talent and labour recruitment and acquiring patents, licences and other intangible assets. A day before it announced its significant capital raise, Lunit disclosed that it received the US FDA approval for its AI 3D Breast Tomosynthesis (DBT) solution.

FUNDING FUNDING ROUND

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING